GlassScriptPhysician profile
Gerard Balan
NPI 1518108455
$4,659.97
in general payments reported to CMS, 2019-2025
19 companies · $48.61 in 2025
The $48.61 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $191 · 2023: $267 · 2024: $4,021 · 2025: $48.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,600 · Food and Beverage: $736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,600.00 |
| Food and Beverage | $736.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $3,738.16 | 2021-2024 | Loreev Xr |
| Neuronetics, INC. | $113.75 | 2022-2024 | Neurostar Tms Therapy System |
| Ironshore Pharmaceuticals INC. | $113.69 | 2023-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $91.14 | 2022-2024 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.96 | 2021-2023 | |
| Alkermes, INC. | $63.96 | 2021-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $62.06 | 2021-2022 | |
| Sage Therapeutics, LLC | $57.58 | 2024 | |
| Tempus Ai, INC | $54.68 | 2024 | |
| Corium, LLC | $46.41 | 2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $37.91 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $34.08 | 2023 | Belsomra |
| Vanda Pharmaceuticals INC. | $33.84 | 2025 | Fanapt |
| Tris Pharma INC | $29.92 | 2023 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $28.61 | 2021-2024 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $28.06 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $23.54 | 2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $18.85 | 2023 | Austedo |
| Collegium Pharmaceutical, INC. | $14.77 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerard Balan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.